AI Article Synopsis
- Metanephric stromal tumor is a rare benign kidney tumor in children that can be effectively treated through nephrectomy, but distinguishing it from more aggressive renal tumors can be challenging.
- Cytogenetic studies of a metanephric stromal tumor in a 3-year-old boy revealed complex genetic changes, specifically a gain in the 17q22 to 17q25.3 region, suggesting this alteration may be significant in diagnosis.
- Further research is necessary to confirm these cytogenetic findings as a common abnormality associated with metanephric stromal tumors.
Article Abstract
Metanephric stromal tumor is a rare benign entity belonging to the group of metanephric renal tumors in children. Although metanephric stromal tumors can be cured by simple nephrectomy, differential diagnosis based on histopathologic criteria with other pediatric renal tumors requiring aggressive chemotherapy can be difficult. To our knowledge, cytogenetic characterization of metanephric stromal tumor has never been reported. We describe conventional ("R-bands" karyotyping) and molecular [fluorescence in situ hybridization (FISH), multicolor FISH, oligo array-comparative genomic hybridization] cytogenetic examinations of a metanephric stromal tumor in a 3-year-old boy. Cytogenetic analysis revealed a complex homogeneous gain between bands 17q22 and 17q25.3, resulting in partial triplication of the segment between bands 17q22 and 17q24.3, and duplication of the segment between bands 17q24.3 and 17q25.3. Cytogenetic confirmatory studies in metanephric stromal tumors are currently needed to assess 17q22q25.3 gain as a recurring cytogenetic abnormality of metanephric stromal tumors.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cancergen.2011.05.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!